55
PerformanceGraph (1)
COMPARISONOF5YEARCUMULATIVETOTALRETURN
Among Isis Pharmaceuticals, Inc., theNASDAQComposite Index,
and theNASDAQBiotechnology Index
Dec-08
Dec-09
Dec-10
Dec-11
Dec-12
Dec-13
Isis Pharmaceuticals, Inc. .............. $
100 $
78.35 $
71.37 $
50.85 $
73.62 $ 280.96
NASDAQComposite Index ......... $
100 $ 144.88 $ 170.58 $ 171.30 $
199.99 $ 283.39
NASDAQBiotechnology Index ... $
100 $ 104.67 $ 112.89 $ 127.04 $
169.50 $ 288.38
(1) This section is not “solicitingmaterial,” is not deemed “filed”with theSEC, is not subject to the liabilities of Section18of the
ExchangeAct and is not tobe incorporatedby reference in any of our filings under theSecuritiesAct or theExchangeAct, whether
made before or after the date hereof and irrespective of anygeneral incorporation language in any such filing.
Item6. SelectedFinancialData
Set forthbelow are our selected consolidated financial data (in thousands, except per share amounts):
YearsEndedDecember 31,
2013
2012
2011
2010
2009
ConsolidatedStatement ofOperationsData:
Revenue ............................................................................... $ 147,285 $ 102,049 $ 99,086 $ 108,473 $ 121,600
Research, development andpatent expenses ....................... $ 184,033 $ 158,458 $ 157,397 $ 145,160 $ 134,623
Net loss from continuingoperations attributable to Isis
Pharmaceuticals, Inc. common stockholders ................... $ (60,644) $ (65,478) $ (84,801) $ (61,251) $ (30,562)
Net income (loss) attributable to Isis Pharmaceuticals,
Inc. common stockholders ............................................... $ (60,644) $ (65,478) $ (84,801) $ (61,251) $ 155,066
Basic anddilutednet loss per share from continuing
operations attributable to Isis Pharmaceuticals, Inc.
common stockholders ...................................................... $ (0.55) $ (0.65) $ (0.85) $
(0.62) $ (0.31)
Basic anddilutednet income (loss) per share attributable
to Isis Pharmaceuticals, Inc. common stockholders ........ $ (0.55) $ (0.65) $ (0.85) $
(0.62) $ 1.58
Shares used in computingbasic anddilutednet income
(loss) per share .................................................................
110,502
100,576
99,656
99,143
98,109
